JP2010512974A - 流動性のキャリア組成物およびその使用方法 - Google Patents
流動性のキャリア組成物およびその使用方法 Download PDFInfo
- Publication number
- JP2010512974A JP2010512974A JP2009543070A JP2009543070A JP2010512974A JP 2010512974 A JP2010512974 A JP 2010512974A JP 2009543070 A JP2009543070 A JP 2009543070A JP 2009543070 A JP2009543070 A JP 2009543070A JP 2010512974 A JP2010512974 A JP 2010512974A
- Authority
- JP
- Japan
- Prior art keywords
- bmp
- composition
- phosphate
- biological
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title description 19
- 230000009969 flowable effect Effects 0.000 title description 6
- 239000002002 slurry Substances 0.000 claims abstract description 55
- 239000007943 implant Substances 0.000 claims abstract description 43
- 239000003124 biologic agent Substances 0.000 claims abstract description 39
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 38
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 36
- 239000007788 liquid Substances 0.000 claims abstract description 35
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 31
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 30
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 30
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 26
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 26
- 230000000399 orthopedic effect Effects 0.000 claims abstract description 12
- 230000008439 repair process Effects 0.000 claims abstract description 6
- -1 calcium phosphate compound Chemical class 0.000 claims description 31
- 239000003181 biological factor Substances 0.000 claims description 25
- 102000008186 Collagen Human genes 0.000 claims description 17
- 108010035532 Collagen Proteins 0.000 claims description 17
- 229920001436 collagen Polymers 0.000 claims description 16
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 10
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 10
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 10
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- 229920001710 Polyorthoester Polymers 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 229960001714 calcium phosphate Drugs 0.000 claims description 6
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 6
- 239000002745 poly(ortho ester) Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000004633 polyglycolic acid Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 5
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 4
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 108090000190 Thrombin Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium phosphate dihydrate Substances O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims description 4
- 230000011164 ossification Effects 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 claims description 3
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 3
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims description 3
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 3
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 3
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 claims description 3
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 claims description 3
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 claims description 3
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 3
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 3
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 3
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 3
- 102000016942 Elastin Human genes 0.000 claims description 3
- 108010014258 Elastin Proteins 0.000 claims description 3
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 3
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 claims description 3
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 claims description 3
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 3
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims description 3
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 3
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 claims description 3
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 claims description 3
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 claims description 3
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 3
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 3
- 102100040682 Platelet-derived growth factor D Human genes 0.000 claims description 3
- 101710170209 Platelet-derived growth factor D Proteins 0.000 claims description 3
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims description 3
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 3
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims description 3
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 3
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 3
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 3
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 230000002051 biphasic effect Effects 0.000 claims description 3
- 108010046910 brain-derived growth factor Proteins 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 3
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 3
- 229920002549 elastin Polymers 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 230000000887 hydrating effect Effects 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 3
- 229920005615 natural polymer Polymers 0.000 claims description 3
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims description 3
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 229920001059 synthetic polymer Polymers 0.000 claims description 3
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 3
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 101150021185 FGF gene Proteins 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 2
- 102400000716 Transforming growth factor beta-1 Human genes 0.000 claims 2
- 102400001359 Transforming growth factor beta-2 Human genes 0.000 claims 2
- 102400000398 Transforming growth factor beta-3 Human genes 0.000 claims 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 2
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 2
- 229940045110 chitosan Drugs 0.000 claims 2
- 229910000150 monocalcium phosphate Inorganic materials 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 abstract description 7
- 230000002138 osteoinductive effect Effects 0.000 abstract description 3
- 239000002245 particle Substances 0.000 abstract description 2
- 238000009736 wetting Methods 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 230000006378 damage Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000014674 injury Diseases 0.000 description 6
- 230000008468 bone growth Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007547 defect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000002188 osteogenic effect Effects 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010050777 Growth Differentiation Factors Proteins 0.000 description 1
- 102000014015 Growth Differentiation Factors Human genes 0.000 description 1
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910000392 octacalcium phosphate Inorganic materials 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00491—Surgical glue applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
- A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00491—Surgical glue applicators
- A61B2017/00495—Surgical glue applicators for two-component glue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/612,853 US8048857B2 (en) | 2006-12-19 | 2006-12-19 | Flowable carrier compositions and methods of use |
| PCT/US2007/087117 WO2008079672A2 (en) | 2006-12-19 | 2007-12-12 | Flowable carrier compositions for orthopedic implants and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512974A true JP2010512974A (ja) | 2010-04-30 |
| JP2010512974A5 JP2010512974A5 (enExample) | 2011-01-13 |
Family
ID=39528417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543070A Withdrawn JP2010512974A (ja) | 2006-12-19 | 2007-12-12 | 流動性のキャリア組成物およびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8048857B2 (enExample) |
| EP (1) | EP2129318A2 (enExample) |
| JP (1) | JP2010512974A (enExample) |
| WO (1) | WO2008079672A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101780579B1 (ko) * | 2016-01-20 | 2017-09-21 | 건양대학교산학협력단 | 주입형 인산칼슘-plga 복합 뼈수복재의 제조방법 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040081704A1 (en) | 1998-02-13 | 2004-04-29 | Centerpulse Biologics Inc. | Implantable putty material |
| US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| US7955616B2 (en) * | 2003-09-23 | 2011-06-07 | Orthocon, Inc. | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
| US8383586B2 (en) * | 2007-01-18 | 2013-02-26 | Warsaw Orthopedic, Inc. | Compositions and methods for soft tissue repair |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| WO2009020744A1 (en) | 2007-08-07 | 2009-02-12 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations comprising gdf-5 in aqueous acidic solution |
| US20090110637A1 (en) * | 2007-10-26 | 2009-04-30 | Warsaw Orthopedic, Inc. | LMP and Regulation of Tissue Growth |
| BRPI0911048A2 (pt) | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| US9616153B2 (en) | 2008-04-17 | 2017-04-11 | Warsaw Orthopedic, Inc. | Rigid bone graft substitute |
| FR2932686B1 (fr) * | 2008-06-23 | 2010-08-27 | Centre Nat Rech Scient | Combinaison de sang et de particules de ceramique de phosphates de calcium biphases. |
| FR2932687B1 (fr) * | 2008-06-23 | 2010-09-17 | Centre Nat Rech Scient | Biomateriaux a base de phosphates de calcium. |
| CN101297980B (zh) * | 2008-07-01 | 2011-11-23 | 北京奥精医药科技有限公司 | 含纳米羟基磷灰石/胶原微粒的骨修复材料及其制备方法 |
| RU2421223C2 (ru) * | 2008-12-15 | 2011-06-20 | Государственное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию" | Способ лечения переломов длинных трубчатых костей при йододефицитных заболеваниях |
| RU2416411C2 (ru) * | 2008-12-22 | 2011-04-20 | Государственное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию" | Способ лечения переломов длинных трубчатых костей |
| AU2011329054B2 (en) | 2010-11-15 | 2015-05-28 | Zimmer Orthobiologics, Inc. | Bone void fillers |
| US8524662B2 (en) | 2010-12-28 | 2013-09-03 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| US8455436B2 (en) | 2010-12-28 | 2013-06-04 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
| EP2688514A1 (en) | 2011-03-21 | 2014-01-29 | Endo Pharmaceuticals Inc. | Urethral anastomosis device and method |
| CN102205149B (zh) * | 2011-05-10 | 2013-10-02 | 中国科学院合肥物质科学研究院 | 羟基磷灰石/壳聚糖/聚乳酸复合骨修复材料及制备方法 |
| US8623839B2 (en) | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| US11484578B2 (en) * | 2012-02-01 | 2022-11-01 | Children's Medical Center Corporation | Biomaterial for articular cartilage maintenance and treatment of arthritis |
| AU2013318237A1 (en) | 2012-09-18 | 2015-04-09 | Goldberg, Roger P. | Urethral anastomosis device |
| WO2014159186A1 (en) | 2013-03-14 | 2014-10-02 | Endo Pharmaceuticals Inc. | Urethral anastomosis device |
| AU2015374114B2 (en) | 2014-12-29 | 2018-07-26 | Bioventus, Llc | Systems and methods for improved delivery of osteoinductive molecules in bone repair |
| US9682099B2 (en) | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
| WO2017011668A1 (en) * | 2015-07-14 | 2017-01-19 | Boston Scientific Scimed, Inc. | Gel delivery catheters, systems, and methods |
| US10300172B2 (en) * | 2015-10-30 | 2019-05-28 | Bioventus, LLC. | Matrix for enhanced delivery of osteoinductive molecules in bone repair |
| US11020160B2 (en) * | 2016-03-21 | 2021-06-01 | Warsaw Orthopedic, Inc. | Surgical injection system and method |
| EP3445411B1 (en) | 2016-04-19 | 2025-02-19 | Warsaw Orthopedic, Inc. | An implantable composite containing carbonated hydroxyapatite |
| CA3026660A1 (en) | 2016-06-10 | 2017-12-14 | Bioventus, Llc | Protein delivery with porous metallic structure |
| EP3938000A4 (en) * | 2019-03-14 | 2022-11-16 | BioMimetic Therapeutics, LLC | PLATELET DERIVED GROWTH FACTOR FORMULATIONS TO IMPROVE BONE FUSION |
| US20200324025A1 (en) * | 2019-04-10 | 2020-10-15 | Globus Medical, Inc. | Compositions containing bone morphogenic proteins and methods therof |
| US12599696B2 (en) | 2019-07-26 | 2026-04-14 | Warsaw Orthopedic, Inc. | Hydratable and flowable implantable compositions and methods of making and using them |
| US11498880B2 (en) | 2019-07-26 | 2022-11-15 | Warsaw Orthopedic, Inc. | Calcium phosphate granules and methods of making them |
| US11433159B2 (en) * | 2019-07-26 | 2022-09-06 | Warsaw Orthopedic, Inc. | Hydratable and flowable implantable compositions and methods of making and using them |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3944655A (en) | 1973-09-10 | 1976-03-16 | Viobin Corporation | Process of preparing food products from bones |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4472840A (en) | 1981-09-21 | 1984-09-25 | Jefferies Steven R | Method of inducing osseous formation by implanting bone graft material |
| NL8402158A (nl) | 1983-07-09 | 1985-02-01 | Sumitomo Cement Co | Poreus keramisch materiaal en werkwijze voor de bereiding daarvan. |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| DE3479402D1 (en) | 1984-06-12 | 1989-09-21 | Oscobal Ag | Method of producing a bone replacement material |
| US5246457A (en) | 1985-03-28 | 1993-09-21 | Collagen Corporation | Xenogeneic collagen/mineral preparations in bone repair |
| US4755593A (en) | 1985-07-24 | 1988-07-05 | Lauren Mark D | Novel biomaterial of cross-linked peritoneal tissue |
| US4698326A (en) | 1985-12-20 | 1987-10-06 | Regents Of The University Of Minnesota | Composition and method for osseous repair |
| US4780450A (en) | 1985-12-20 | 1988-10-25 | The University Of Maryland At Baltimore | Physically stable composition and method of use thereof for osseous repair |
| US6311690B1 (en) | 1986-03-27 | 2001-11-06 | Gensci Orthobiologics, Inc. | Bone repair material and delayed drug delivery system |
| US4865602A (en) | 1986-11-06 | 1989-09-12 | Collagen Corporation | Gamma irradiation of collagen/mineral mixtures |
| FR2617488B1 (fr) | 1987-07-01 | 1990-03-09 | Tab | Procede de fabrication de structures organisees de collagene, notamment d'origine humaine, et structures organisees de collagene correspondantes |
| JPH0773602B2 (ja) | 1988-07-23 | 1995-08-09 | 新田ゼラチン株式会社 | 医科用および歯科用硬化性材料 |
| US5231169A (en) | 1990-10-17 | 1993-07-27 | Norian Corporation | Mineralized collagen |
| GB9122329D0 (en) | 1991-10-22 | 1991-12-04 | Isis Innovation | Bioactive material |
| US5320844A (en) | 1992-03-12 | 1994-06-14 | Liu Sung Tsuen | Composite materials for hard tissue replacement |
| US5532217A (en) | 1992-04-24 | 1996-07-02 | Silver; Frederick H. | Process for the mineralization of collagen fibers, product produced thereby and use thereof to repair bone |
| US5531791A (en) | 1993-07-23 | 1996-07-02 | Bioscience Consultants | Composition for repair of defects in osseous tissues, method of making, and prosthesis |
| US5707962A (en) | 1994-09-28 | 1998-01-13 | Gensci Regeneration Sciences Inc. | Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof |
| US6180606B1 (en) | 1994-09-28 | 2001-01-30 | Gensci Orthobiologics, Inc. | Compositions with enhanced osteogenic potential, methods for making the same and uses thereof |
| US5674292A (en) | 1995-06-07 | 1997-10-07 | Stryker Corporation | Terminally sterilized osteogenic devices and preparation thereof |
| US6902584B2 (en) | 1995-10-16 | 2005-06-07 | Depuy Spine, Inc. | Bone grafting matrix |
| US5776193A (en) | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
| US6048964A (en) | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
| CA2221195A1 (en) | 1997-11-14 | 1999-05-14 | Chantal E. Holy | Biodegradable polymer matrix |
| WO2000007639A1 (en) | 1998-08-07 | 2000-02-17 | Tissue Engineering, Inc. | Bone precursor compositions |
| ES2187195T3 (es) | 1998-09-11 | 2003-05-16 | Gerhard Dr Schmidmaier | Implantes biologicamente activos. |
| DE69918717T2 (de) * | 1998-12-14 | 2005-07-21 | Osteotech, Inc. | Knochentransplantat aus knochenpartikel |
| ES2209820T3 (es) * | 1999-02-04 | 2004-07-01 | Sdgi Holdings, Inc. | Composiciones esponjosas osteogenicas altamente mineralizadas, y usos de las mismas. |
| AU2984700A (en) | 1999-02-12 | 2000-08-29 | Collagenesis, Inc. | Injectable collagen-based delivery system for bone morphogenic proteins |
| US6300315B1 (en) | 1999-08-28 | 2001-10-09 | Ceramedical, Inc. | Mineralized collagen membrane and method of making same |
| ATE271886T1 (de) | 1999-10-15 | 2004-08-15 | Inst Genetics Llc | Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine |
| EP1481695A1 (en) | 1999-10-15 | 2004-12-01 | Genetics Institute, LLC | Formulations of hyaluronic acid for delivery of osteogenic proteins |
| CA2396016A1 (en) * | 1999-12-29 | 2001-07-05 | Andy Bernhardt | System for reconstituting pastes and methods of using same |
| WO2001054746A2 (en) | 2000-01-31 | 2001-08-02 | Advanced Research And Technology Institute, Inc. | Composite biomaterial including anisometric calcium phosphate reinforcement particles |
| AU2001244021A1 (en) * | 2000-04-26 | 2001-11-07 | Ecole Polytechnique Federale De Lausanne (Epfl) | Calcium phosphate microgranules |
| US6485751B1 (en) | 2000-05-30 | 2002-11-26 | Industrial Technology Research Institute | Resorbable calcium phosphate-based bio-compound particles and the manufacturing procedure thereof |
| DE10029520A1 (de) | 2000-06-21 | 2002-01-17 | Merck Patent Gmbh | Beschichtung für metallische Implantatmaterialien |
| DE10037850A1 (de) | 2000-08-01 | 2002-02-21 | Herbert P Jennissen | Verfahren zur Herstellung bioaktiver Implantatoberflächen |
| JP2002210002A (ja) | 2001-01-18 | 2002-07-30 | Foundation For Nara Institute Of Science & Technology | 生体組織修復用組成物 |
| JP2004533276A (ja) | 2001-01-25 | 2004-11-04 | リジェネレーション テクノロジーズ インク． | 注射可能な多孔性骨グラフト材料 |
| US6969523B1 (en) | 2001-10-19 | 2005-11-29 | Integra Lifesciences Corporation | Collagen/glycosaminoglycan matrix stable to sterilizing by electron beam radiation |
| CH695985A5 (de) | 2002-01-21 | 2006-11-15 | Straumann Holding Ag | Oberflächenmodifizierte Implantate. |
| US7166133B2 (en) * | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
| CA2839032A1 (en) * | 2003-05-19 | 2005-01-06 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof |
| US20050020506A1 (en) | 2003-07-25 | 2005-01-27 | Drapeau Susan J. | Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use |
| DE602004005477T2 (de) | 2003-09-12 | 2007-12-13 | Wyeth | Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen |
| WO2005070439A1 (en) * | 2004-01-09 | 2005-08-04 | Regeneration Technologies Inc. | Implant comprising a human muscle tissue matrix |
| DE202004005420U1 (de) | 2004-03-31 | 2005-08-18 | Technische Universität Dresden | Modifizierter Calciumphosphatzement |
| US20080031914A1 (en) | 2006-08-02 | 2008-02-07 | Drapeau Susan J | Flowable biomaterial composition |
-
2006
- 2006-12-19 US US11/612,853 patent/US8048857B2/en active Active
-
2007
- 2007-12-12 EP EP07865523A patent/EP2129318A2/en not_active Ceased
- 2007-12-12 WO PCT/US2007/087117 patent/WO2008079672A2/en not_active Ceased
- 2007-12-12 JP JP2009543070A patent/JP2010512974A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101780579B1 (ko) * | 2016-01-20 | 2017-09-21 | 건양대학교산학협력단 | 주입형 인산칼슘-plga 복합 뼈수복재의 제조방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8048857B2 (en) | 2011-11-01 |
| WO2008079672A3 (en) | 2008-12-24 |
| US20080147065A1 (en) | 2008-06-19 |
| WO2008079672A2 (en) | 2008-07-03 |
| WO2008079672A4 (en) | 2009-02-19 |
| EP2129318A2 (en) | 2009-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8048857B2 (en) | Flowable carrier compositions and methods of use | |
| US8198238B2 (en) | Flowable carrier matrix and methods for delivering to a patient | |
| Schmidmaier et al. | Carrier systems and application of growth factors in orthopaedics | |
| US8106008B2 (en) | Compositions and methods for arthrodetic procedures | |
| US11786634B2 (en) | Demineralized bone matrix having improved handling characteristics | |
| Calori et al. | Bone morphogenetic proteins and tissue engineering: future directions | |
| Damron | Use of 3D β-tricalcium phosphate (Vitoss®) scaffolds in repairing bone defects | |
| JP2009536078A (ja) | 骨粗鬆症の骨を処置するための成長因子送達用のインプラントデポー | |
| KR20140038348A (ko) | 척추 유합 절차를 위한 조성물 및 방법 | |
| US20250032673A1 (en) | Bone repair composition and kit | |
| Beck et al. | Combination of bone marrow and TGF‐β1 augment the healing of critical‐sized bone defects | |
| Cheung | The future of bone healing | |
| Kirker-Head et al. | Use of bone morphogenetic proteins for augmentation of bone regeneration | |
| CN111867561A (zh) | 可注射骨形态发生蛋白 | |
| WO2025042830A1 (en) | Platelet-derived growth factor bone graft putty formulation | |
| HK40019925B (zh) | 自体骨移植物替代物 | |
| McKay et al. | Local Delivery of Bone Growth Factors | |
| Hannouche et al. | Marrow Stromal Cells in Orthopedic Surgery | |
| Tölli | Reindeer-derived bone protein extract in the healing of bone defects: evaluation of various carrier materials and delivery systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101119 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20120416 |